CRISPR Therapeutics AG (CRSP)

Market Cap	5.25B
Revenue (ttm)	38.34M
Net Income (ttm)	-488.30M
Shares Out	95.30M
EPS (ttm)	-5.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,410,168
Open	56.48
Previous Close	56.71
Day's Range	53.76 - 56.54
52-Week Range	30.04 - 78.48
Beta	1.73
Analysts	Buy
Price Target	71.50 (+29.81%)
Earnings Date	Feb 10, 2026

About CRSP

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 19, 2016
• Employees: 393
• Stock Exchange: NASDAQ
• Ticker Symbol: CRSP
• Website: https://www.crisprtx.com

Financial Performance

In 2024, CRISPR Therapeutics AG's revenue was $37.31 million, a decrease of -89.95% compared to the previous year's $371.21 million. Losses were -$366.25 million, 138.4% more than in 2023.

Analyst Summary

According to 19 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price target is $71.5, which is an increase of 29.81% from the latest price.

Price Target

$71.5

(29.81% upside)

Analyst Consensus: Buy